Le, Amy http://orcid.org/0000-0002-1489-7133
Amin, Mitual http://orcid.org/0000-0002-0558-2615
Cappell, Mitchell S. http://orcid.org/0000-0003-3445-5428
Article History
Received: 8 August 2018
Accepted: 22 January 2019
First Online: 6 February 2019
Compliance with ethical standards
:
: None. In particular, Dr. Cappell, as a consultant of the United States Food and Drug Administration (FDA) Advisory Committee for Gastrointestinal Drugs, affirms that this paper does not discuss any proprietary confidential pharmaceutical data submitted to the FDA. Dr. Cappell was a member of the speaker’s bureau for AstraZeneca and Daiichi Sankyo, co-marketers of Movantik and did receive one-time consulting fees from Mallinckrodt and Shire. This work does not discuss any drug manufactured or marketed by AstraZeneca, Daiichi Sankyo, Shire, or Mallinckrodt.
: This study received approval from the IRB of William Beaumont Hospital at Royal Oak on June 27, 2018.